Laniquidar is a third-generation P-gp inhibitor, which has been used in clinic trials for modulating multidrug resistance transporters. A study of docetaxel in combination with the new orally administered P-glycoprotein (P-gp) inhibitor R101933 showed that this combination was feasible. However, due to the low orally bioavailable bioavailability of R101933 and high interpatient variability, no further attempts to increase the level of P-gp inhibition were made. References: Moerman L, Dumolyn C, Boon P, De Vos F. The influence of mass of [11C]-laniquidar and [11C]-N-desmethyl-loperamide on P-glycoprotein blockage at the blood-brain barrier. Nucl Med Biol. 2012 Jan;39(1):121-5. Epub 2011 Sep 29. PubMed PMID: 21958857.

纯度：≥98%

CAS：197509-46-9